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Background
Lung cancer is the most common cause of cancer-related
mortality worldwide. Survival rates after non-small cell
lung cancer (NSCLC) diagnosis still remain poor, despite
standardization of surgery and adjuvant treatment. Can-
cer testis (CT) antigens as targets for immunotherapy in
cancer patients have been heavily investigated. We aim to
evaluate the expression of CT antigens in non-small cell
lung cancer and the correlation with the clinical
characteristics.
Methods
The expression of MAGE-A3, MAGE-A4, MAGE-C2 and
NY-ESO-1 in fresh cancer tissues from 113 patients with
non-small cell lung cancer were analyzed by RT-PCR. The
expression of HLA-A2 was detected by flow cytometry.
Results
49.6% non-small cell lung cancer samples were HLA-A2
positive. CT antigens were frequently expressed in non-
small cell lung cancer. The expression percentage of each
gene in cancer tissues samples were as follows: MAGE-
A3, 70.8%; MAGE-A4, 46.9%; MAGE-C2, 61.1%; and
NY-ESO-1, 15.0%. In all, Seventeen tissues did not
express any of the CT antigens tested, 85.0% expressed at
least one, 66.4% co-expressed two, 34.5% co-expressed
three, 6.2% co-expressed four examined CT antigens.
The percentage of samples co-expression HLA-A2 and
CT genes were: MAGE-A3, 51.6%; MAGE-A4, 36.3%;
MAGE-C2, 44.0%; and NY-ESO-1, 12.1%. MAGE-A3 was
associated with male, smoking history, tumor stage,
tumor differentiation and lymph node metastasis
(P<0.05); MAGE-C2 was associated with tumor stage
(P<0.05). There was no correlation MAGE-A4 or NY-
ESO-1 expression with clinical characteristics such as
gender, age, HLA-A2 positive, clinical stage, grade of dif-
ferentiation and lymph node metastasis (P>0.05).
Conclusion
CT antigens might be prognostic markers and factors
related to the progress of NSCLC, and also be served as
the immunotherapeutic targets of NSCLC, especially in
multi-antigen vaccine preparations and tumor antigen
specific lymphocytes infusion.
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